Search

Displaying results 4911 - 4920 of 5449 in total
  1. Drug

    Influenza A virus A/South Australia/55/2014 IVR-175 (H3N2) antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB10601
    ApprovedWithdrawn

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it

  2. Drug

    Influenza A virus A/California/7/2009 (H1N1) recombinant hemagglutinin antigen

    go.drugbank.com/drugs/DB10773
    ApprovedInvestigationalWithdrawn

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it

  3. Drug

    Influenza B virus B/Phuket/3073/2013 recombinant hemagglutinin antigen

    go.drugbank.com/drugs/DB10779
    ApprovedInvestigational

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it

  4. Drug

    Influenza A virus A/Christchurch/16/2010 NIB-74XP (H1N1) antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB10996
    ApprovedWithdrawn

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it

  5. Drug

    Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB11038
    ApprovedWithdrawn

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it

  6. Drug

    Influenza A virus A/Uruguay/716/2007(H3N2) hemagglutinin antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB11039
    ApprovedWithdrawn

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it

  7. Drug

    Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB11043
    ApprovedWithdrawn

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it

  8. Drug

    Influenza A virus A/Texas/50/2012 X-223 (H3N2) antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB11045
    ApprovedWithdrawn

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it

  9. Drug

    Influenza A virus A/California/7/2009(H1N1)-like hemagglutinin antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB11048
    ApprovedWithdrawn

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it

  10. Drug

    Agkistrodon piscivorus antivenin

    go.drugbank.com/drugs/DB13894
    Approved

    It is intravenously (IV) administered to limit/prevent systemic toxicity [FDA label].